Cantor Fitzgerald Global Healthcare Conference. On Wednesday, September 27, 2017, Keith Orford, M.D., Ph.D., Senior Vice President of Clinical Development, will present a corporate update at 9:10 a.m. EDTat the Cantor Fitzgerald Global Healthcare Conferencein New York City.
- Leerink Partners Immuno-Oncology Roundtable. On
Thursday, September 28, 2017, Dr. Orford will participate in a fireside chat to discuss recent corporate developments at the Leerink Partners Immuno-Oncology Roundtable being held in New York Cityat 8:30 a.m. EDT.
The presentations will be webcast live, and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera Biosciences
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing of Calithera’s clinical trials, the clinical and commercial potential of its product candidates, Calithera’s ability to fund its clinical programs, and Calithera’s receipt of clinical data from its clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the
Source: Calithera Biosciences, Inc.